Dec 06, 2020
CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 20, 2020
CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December
Oct 05, 2020
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
Aug 20, 2020
CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells
Aug 17, 2020
CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion
May 18, 2020
CARsgen Therapeutics Receives IND Clearance from the US FDA for CT041 CLDN18.2-CAR-T Cells
Apr 27, 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
Jan 06, 2020
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
Dec 09, 2019
CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody
Oct 28, 2019
CARsgen Announces Investigational CAR-T Therapy CT053 Granted RMAT Designation by the U.S. FDA for R/R Multiple Myeloma
Sep 23, 2019
CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency
Aug 30, 2019
CARsgen Therapeutics Receives US FDA Orphan Drug Designation For Fully Human Anti-BCMA (B Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cells For The Treatment Of Multiple Myeloma
Jun 19, 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the U.S. FDA
Mar 01, 2019
CARsgen Therapeutics Receives IND Clearance for BCMA-CAR-T Cells from the NMPA
Jan 29, 2019
CARsgen Therapeutics Receives IND Clearance for GPC3-CAR-T Cells from the NMPA
Mar 02, 2018
CARsgen Completed $60 Million Pre-C Financing Framework Agreements
Jun 23, 2017
CARsgen Therapeutics Presented at the 2017 BIO International Convention